Revisiting the Pathology of Resected Benign Hepatocellular Nodules Using New Immunohistochemical Markers

ABSTRACT

In this review, the authors focus on the use of immunohistochemistry to characterize the different types and subtypes of benign hepatocellular nodules. They describe the classical and currently accepted features leading to the easy and formal diagnosis of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA). In addition, they report some atypical features and difficulties in the interpretation of section staining analyses, which represent important parameters for pathologists. A significant contribution of molecular biology to the characterization of FNH has been to reclassify some cases of FNH as inflammatory HCA. Furthermore, the pattern of overexpression of glutamine synthetase (GS), a target gene of β-catenin has been successfully used to identify FNH by immunohistochemistry. Molecular approaches have demonstrated that HCA is a heterogeneous entity. Genotype classification of HCA has allowed the identification of three subtypes: HNF1A-mutated HCA (H-HCA) in 35% of cases, β-catenin-mutated HCA (b-HCA) in 10%, and inflammatory HCA (IHCA) in 55%. Following molecular data, the diagnosis of H-HCA relies on the lack of liver fatty acid binding protein (LFABP) immunostaining. The diagnosis of b-HCA is straightforward when GS is strongly and diffusely expressed by lesional hepatocytes, and is accompanied by nuclear β-catenin immunoreactivity. In IHCA, serum amyloid protein and C- reactive protein are strongly and usually diffusely expressed by tumoral hepatocytes with a sharp limit with the surrounding nontumoral liver. IHCA can also be β-catenin activated (10%). Due to the strong association of b-HCA with hepatocellular carcinoma transformation, the identification of this HCA subtype is extremely important.

Focal nodular hyperplasia - hepatocellular adenoma - HNF1A-mutated hepatocellular adenoma - β-catenin-mutated hepatocellular adenoma - inflammatory hepatocellular adenoma

REFERENCES

• 1 Bioulac-Sage P, Laumonier H, Balabaud C. Benign hepatocellular tumors. In: Saxena R, ed. Practical Hepatic Pathology: A Diagnostic Approach. Philadelphia: Saunders; 2011. In press
• 2 Bioulac-Sage P, Balabaud C, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman F, Carneiro F, Hruban R, Theise N D, eds. Tumors of the Digestive Tract. Lyon, France: World Health Organization, IARC; 2010: 198-204
• 3 Bluteau O, Jeannot E, Bioulac-Sage P et al.. Bi-allelic inactivation of TCF1 in hepatic adenomas.  Nat Genet. 2002;  32 (2) 312-315
• 4 Zucman-Rossi J, Jeannot E, Nhieu J T et al.. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.  Hepatology. 2006;  43 (3) 515-524
• 5 Rebouissou S, Amessou M, Couchy G et al.. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.  Nature. 2009;  457 (7226) 200-204
• 6 Bioulac-Sage P, Rebouissou S, Thomas C et al.. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.  Hepatology. 2007;  46 (3) 740-748
• 7 Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.  J Hepatol. 2008;  48 (1) 163-170
• 8 Bioulac-Sage P, Balabaud C, Bedossa P Laennec and Elves groups et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update.  J Hepatol. 2007;  46 (3) 521-527
• 9 Paradis V, Laurent A, Flejou J F, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation.  Hepatology. 1997;  26 (4) 891-895
• 10 Paradis V, Bièche I, Dargère D et al.. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia.  Gastroenterology. 2003;  124 (3) 651-659
• 11 Rebouissou S, Couchy G, Libbrecht L et al.. The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.  J Hepatol. 2008;  49 (1) 61-71
• 12 Paradis V, Benzekri A, Dargère D et al.. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma.  Gastroenterology. 2004;  126 (5) 1323-1329
• 13 Bioulac-Sage P, Rebouissou S, Sa Cunha A et al.. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.  Gastroenterology. 2005;  128 (5) 1211-1218
• 14 Bioulac-Sage P, Laumonier H, Rullier A et al.. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology.  Liver Int. 2009;  29 (3) 459-465
• 15 Wanless I R, Albrecht S, Bilbao J et al.. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome.  Mod Pathol. 1989;  2 (5) 456-462
• 16 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Focal nodular hyperplasia, hepatocellular adenomas: past, present, future.  Gastroenterol Clin Biol. 2010;  34 (6–7) 355-358
• 17 Bioulac-Sage P, Laumonier H, Couchy G et al.. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.  Hepatology. 2009;  50 (2) 481-489
• 18 Flejou J F, Barge J, Menu Y et al.. Liver adenomatosis. An entity distinct from liver adenoma?.  Gastroenterology. 1985;  89 (5) 1132-1138
• 19 Lepreux S, Laurent C, Blanc J F et al.. The identification of small nodules in liver adenomatosis.  J Hepatol. 2003;  39 (1) 77-85
• 20 Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification.  Hepatology. 2008;  48 (3) 808-818
• 21 Bacq Y, Jacquemin E, Balabaud C et al.. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation.  Gastroenterology. 2003;  125 (5) 1470-1475
• 22 Reznik Y, Dao T, Coutant R et al.. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families.  J Clin Endocrinol Metab. 2004;  89 (3) 1476-1480
• 23 Jeannot E, Mellottee L, Bioulac-Sage P Groupe d'étude Génétique des Tumeurs Hépatiques (INSERM Network) et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage.  Diabetes. 2010;  59 (7) 1836-1844
• 24 Pelletier L, Rebouissou S, Paris A et al.. Loss of HNF1a function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.  Hepatology. 2010;  51 (2) 557-566
• 25 Jeannot E, Poussin K, Chiche L et al.. Association of CYP1B1 germline mutations with HNF1a mutated hepatocellular adenoma.  Cancer Res. 2007;  67 (6) 2611-2616
• 26 Ladeiro Y, Couchy G, Balabaud C et al.. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.  Hepatology. 2008;  47 (6) 1955-1963
• 27 Rebouissou S, Imbeaud S, Balabaud C et al.. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.  J Biol Chem. 2007;  282 (19) 14437-14446
• 28 Micchelli S T, Vivekanandan P, Boitnott J K, Pawlik T M, Choti M A, Torbenson M. Malignant transformation of hepatic adenomas.  Mod Pathol. 2008;  21 (4) 491-497
• 29 Paradis V, Champault A, Ronot M et al.. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation.  Hepatology. 2007;  46 (1) 140-146
• 30 Bioulac-Sage P, Laumonier H, Cubel G, Rossi J Z, Balabaud C. Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins.  Liver Int. 2010;  30 (1) 149-154
• 31 Sa Cunha A, Blanc J F, Lazaro E et al.. Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management.  Gut. 2007;  56 (2) 307-309
• 32 Cassiman D, Libbrecht L, Verslype C et al.. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia.  J Hepatol. 2010;  53 (1) 213-217
• 33 Velazquez I, Alter B P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions.  Am J Hematol. 2004;  77 (3) 257-267
• 34 Svrcek M, Jeannot E, Arrivé L et al.. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis.  Eur J Endocrinol. 2007;  156 (6) 617-621
• 35 Jeannot E, Wendum D, Paye F et al.. Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli.  J Hepatol. 2006;  45 (6) 883-886
• 36 Toso C, Rubbia-Brandt L, Negro F, Morel P, Mentha G. Hepatocellular adenoma and polycystic ovary syndrome.  Liver Int. 2003;  23 (1) 35-37
• 37 Watkins J, Balabaud C, Bioulac-Sage P, Sharma D, Dhillon A. Hepatocellular adenoma in advanced-stage fatty liver disease.  Eur J Gastroenterol Hepatol. 2009;  21 (8) 932-936
• 38 Brunt E M, Wolverson M K, Di Bisceglie A M. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report.  Semin Liver Dis. 2005;  25 (2) 230-236
• 39 Terkivatan T, Ijzermans J N. Hepatocellular adenoma: Should phenotypic classification direct management?.  Nat Rev Gastroenterol Hepatol. 2009;  6 (12) 697-698
• 40 Dokmak S, Paradis V, Vilgrain V et al.. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas.  Gastroenterology. 2009;  137 (5) 1698-1705
• 41 Veteläinen R, Erdogan D, de Graaf W et al.. Liver adenomatosis: re-evaluation of aetiology and management.  Liver Int. 2008;  28 (4) 499-508